Lilly Launches Trulicity in the US First Ever Ready-to-Use Once-Weekly GLP-1 Receptor Agonist Twitter summary: @LillyDiabetes launches Trulicity in the US first ready-to-use once-weekly GLP-1, available w/savings program for commercially insured On November 10, Eli Lilly and company announced that Trulicity (dulaglutide) is now available in the US, making it the first ready-to-use once weekly GLP-1 receptor agonist to reach the market (no mixing required)
The Epworth Sleepiness Scale (ESS) score was applied in order to estimate the clinical impact on EDS
Clearly, the currently used IPV and OPV have drawbacks in their manufacturing and application
WuXi Biologics scaled an end-to-end digital QA platform, allowing simultaneous FDA, EMA, and NMPA review of batch records, a service differentiator in audit-heavy therapeutic areas
Those experiencing significant issues may benefit from consulting with healthcare professionals regarding over-the-counter remedies or dietary adjustments
Data were analyzed with GraphPad Prism 8 [25]
